Charles Schwab Investment Management Inc. Has $11.13 Million Holdings in Sanofi $SNY

Charles Schwab Investment Management Inc. boosted its stake in Sanofi (NASDAQ:SNY - Free Report) by 32.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 200,615 shares of the company's stock after purchasing an additional 48,670 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in Sanofi were worth $11,126,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Accent Capital Management LLC acquired a new position in Sanofi in the first quarter valued at about $29,000. Eastern Bank raised its stake in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Golden State Wealth Management LLC raised its stake in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Brentview Investment Management LLC acquired a new position in Sanofi in the first quarter valued at about $42,000. Finally, UMB Bank n.a. raised its stake in Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $62.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $51.35 on Monday. The stock has a market cap of $126.09 billion, a P/E ratio of 12.34, a price-to-earnings-growth ratio of 1.22 and a beta of 0.48. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock's 50-day moving average is $48.62 and its 200-day moving average is $51.71. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.73 earnings per share. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.